Biocell Center

La/Es adopts Eastman Acetate Renew to complete its portfolio of sustainable solutions

Retrieved on: 
Friday, September 23, 2022

Eastman Acetate Renew is an acetate flake made from a combination of 60% biobased and 40% certified recycled content.

Key Points: 
  • Eastman Acetate Renew is an acetate flake made from a combination of 60% biobased and 40% certified recycled content.
  • * Produced by Eastman's innovative molecular recycling technology, Acetate Renew is indistinguishable from traditional acetate, offering the same high-quality performance and premium "look and feel" that consumers expect from acetate eyewear but with up to 100% sustainable content.
  • Made with hard to recycle plastic waste, Acetate Renew helps reduce landfill and significantly lower greenhouse gas emissions.
  • "By including Acetate Renew in our product range, La/Es is able to offer sustainable options on all our designs," said Luca Brugnoni, sales director at La/Es.

La/Es adopts Eastman Acetate Renew to complete its portfolio of sustainable solutions

Retrieved on: 
Friday, September 23, 2022

Eastman Acetate Renew is an acetate flake made from a combination of 60% biobased and 40% certified recycled content.

Key Points: 
  • Eastman Acetate Renew is an acetate flake made from a combination of 60% biobased and 40% certified recycled content.
  • * Produced by Eastman's innovative molecular recycling technology, Acetate Renew is indistinguishable from traditional acetate, offering the same high-quality performance and premium "look and feel" that consumers expect from acetate eyewear but with up to 100% sustainable content.
  • Made with hard to recycle plastic waste, Acetate Renew helps reduce landfill and significantly lower greenhouse gas emissions.
  • "By including Acetate Renew in our product range, La/Es is able to offer sustainable options on all our designs," said Luca Brugnoni, sales director at La/Es.

Malaysian Genomics Grows Presence in Thailand

Retrieved on: 
Friday, September 23, 2022

Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.

Key Points: 
  • Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.
  • Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin, said, "We are looking forward to a fruitful relationship with our Thai partners, Salus and Acquest.
  • We look forward to collaborating with Malaysian Genomics and with Salus Healthcare on research and development involving cell regeneration products."
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

Akron Zips Football Starts the 2022 Season with New AstroTurf and a Branding Refresh

Retrieved on: 
Thursday, July 7, 2022

DALTON, Ga., July 7, 2022 /PRNewswire-PRWeb/ -- The University of Akron (UA) installs a new AstroTurf® field at InfoCision Stadium-Summa Field, the home turf for Akron Zips Football. The new field combines excellent durability and aesthetics, giving the players a long-lasting, high-performance turf while elevating the game-day experience for Zips fans, who get to watch their favorite college football team play on a field made by the leading innovator in the synthetic turf industry.

Key Points: 
  • The University of Akron (UA) installs a new AstroTurffield at InfoCision Stadium-Summa Field, the home turf for Akron Zips Football.
  • DALTON, Ga., July 7, 2022 /PRNewswire-PRWeb/ -- The University of Akron (UA) installs a new AstroTurf field at InfoCision Stadium-Summa Field, the home turf for Akron Zips Football.
  • But a better athletic surface and streamlined branding are only part of the changes UA Football is experiencing in 2022.
  • The Akron Zips have an impressive 520 football wins overall and competes in the competitive Mid-American Conference as an NCAA Football Bowl Subdivision (FBS) program.

Rx Holdings Acquires Biocel Access Solutions

Retrieved on: 
Thursday, March 31, 2022

NEW HYDE PARK, N.Y., March 31, 2022 (GLOBE NEWSWIRE) -- Rx Holdings, the parent company of InfinityRx and eScript360, acquired Biocel Access Solutions, realizing the complete design, fulfillment, and delivery of Patient Service Programs that are sponsored by pharmaceutical manufacturers.

Key Points: 
  • NEW HYDE PARK, N.Y., March 31, 2022 (GLOBE NEWSWIRE) -- Rx Holdings, the parent company of InfinityRx and eScript360, acquired Biocel Access Solutions, realizing the complete design, fulfillment, and delivery of Patient Service Programs that are sponsored by pharmaceutical manufacturers.
  • Biocel Access Solutions is a consulting group that has served specialty, compounding, and home infusion pharmacies and is led by Richard (Rick) A. Ford, who is also the former Vice President of Market Access for Trialcard.
  • Biocel is designing solutions for emerging challenges, InfinityRx administers over those solutions, and eScript360 will deliver.
  • Biocel Access Solutions, located in Orlando, Florida, is a design and advisory service group that supports pharma manufacturer-sponsored Patient Service Programs.

The Ingredient Transparency Center's Collagen Stewardship Alliance Adds BioCell Technology to its Supporter List

Retrieved on: 
Thursday, July 15, 2021

SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.

Key Points: 
  • SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.
  • BioCell Collagen is a clinically studied dietary supplement ingredient comprised of a complex matrix of primarily collagen type II peptides, chondroitin sulfate and hyaluronic acid.
  • "BioCell's values surrounding attribution of science and commitment to the collagen category align closely with CSA's and we're pleased to add them to our supporter roster," said Len Monheit, CEO, Trust Transparency Center and management lead for the Collagen Stewardship Alliance.
  • BioCell Collagen is a clinically studied dietary ingredient composed of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate, hyaluronic acid.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Retrieved on: 
Monday, July 12, 2021

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic

Retrieved on: 
Monday, July 12, 2021

LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.

Key Points: 
  • LUND, Sweden, July 12, 2021 /PRNewswire/ -- Amniotics AB (publ) ("Amniotics" or the "Company"), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market.
  • The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid.
  • Lead candidate PulmoStem, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022.
  • With the proceeds from the IPO, Amniotics has the financial resources required to move our lead candidate PulmoStem into clinical development.

Stem Cell Manufacturing in Stem Cell Therapy, Drug Discovery & Development, Stem Cell Banking, and More (2020-2025)

Retrieved on: 
Monday, February 17, 2020

The Stem Cell Manufacturing market is projected to grow with a CAGR of nearly 3.3% over the forecast period.

Key Points: 
  • The Stem Cell Manufacturing market is projected to grow with a CAGR of nearly 3.3% over the forecast period.
  • The major factors attributing to the growth of the market include the technological advancements in stem cell manufacturing and preservation and growing public awareness about the therapeutic potency of stem cell products.
  • Stem Cell Banking Segment is the Fastest Growing Segment in the Stem Cell Manufacturing Market.
  • Stem cell bank is a provision that stores stem cells developed from amniotic fluid for future use.